Opendata, web and dolomites

NSC-Reconstruct SIGNED

Novel Strategies for Cell-based Neural Reconstruction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NSC-Reconstruct project word cloud

Explore the words cloud of the NSC-Reconstruct project. It provides you a very rough idea of what is the project "NSC-Reconstruct" about.

reconstruction    tolerant    treat    starting    donor    carry    neuron    neurodegenerative    trauma    science    authenticity    area    nsc    injuries    disorders    functionally    stroke    cerebral    clinically    structure    functions    innovative    grafted    ultimately    cell    move    local    functional    stem    situ    function    pave    ed    forming    clinical    cortex    connections    appropriate    will    cns    transform    pluripotent    huntington    unmet    projections    networks    generation    neurological    enhanced    comprising    composition    entering    repairing    disorder    human    immunogenicity    incorporating    brain    types    modules    reprogramming    disease    groundbreaking    diseases    parkinson    cells    groups    restoring    reconstruct    compositions    patient    grafting    neuronal    immune    pd    pioneering    damaged    therapies    single    trials    embryonic    circuit    distance    restoration    replacement    repair    optimization    minimized    network   

Project "NSC-Reconstruct" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI MILANO 

Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122
website: www.unimi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 8˙169˙231 €
 EC max contribution 8˙168˙495 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 1˙518˙495.00
2    LUNDS UNIVERSITET SE (LUND) participant 930˙000.00
3    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 780˙000.00
4    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 680˙000.00
5    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 680˙000.00
6    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 680˙000.00
7    CARDIFF UNIVERSITY UK (CARDIFF) participant 500˙000.00
8    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) participant 500˙000.00
9    VIB BE (ZWIJNAARDE - GENT) participant 500˙000.00
10    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 400˙000.00
11    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 400˙000.00
12    LIFE AND BRAIN GMBH DE (BONN) participant 300˙000.00
13    NOVO NORDISK A/S DK (BAGSVAERD) participant 300˙000.00

Map

 Project objective

Neurodegenerative diseases and brain injuries affect large patient groups and carry large unmet clinical needs. NSC-Reconstruct will respond to these needs by developing innovative therapies based on cell replacement, cell reprogramming and circuit reconstruction that have the potential to transform how we treat a wide range of neurological diseases and disorders. In this area of clinical science European research has generated groundbreaking knowledge that has resulted in a pioneering human embryonic stem cell-derived product that is now entering clinical trials for Parkinson’s Disease (PD). In NSC-Reconstruct we will move beyond the replacement of a single neuronal type towards future cell therapies with enhanced authenticity, functions and compositions. NSC-Reconstruct will address PD as an example of disorder for which single neuron replacement has been developed. Our focus in PD will be on incorporating improved cell types and on local network reconstruction. We will also work on repairing long distance networks such as those affected in Huntington’s disease and finally in restoring the complex networks and projections of the cerebral cortex to achieve effective repair in conditions known to affect this structure, such as trauma or stroke. NSC-Reconstruct will lead to (i) the generation of neuronal types with clinically relevant functionality starting from human pluripotent stem cells or through in situ reprogramming, (ii) the optimization of donor cell composition through grafting of functional modules comprising distinct cell types capable of forming appropriate connections, (iii) the restoration of function through the reconstruction of these damaged connections and finally (iv) a greater understanding of the immunogenicity of grafted cells and how this can be minimized. Ultimately, NSC-Reconstruct will provide unique knowledge and products that will pave the way for future CNS cell replacement therapies using functionally enhanced and immune-tolerant cells.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NSC-RECONSTRUCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NSC-RECONSTRUCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

Vacc-iNTS (2019)

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Read More